2012 European thyroid association guidelines for metastatic medullary thyroid cancer. - Wikidata - wikimedia - TriplyDB

2012 European thyroid association guidelines for metastatic medullary thyroid cancer.

2012 European thyroid association guidelines for metastatic medullary thyroid cancer.

http://www.wikidata.org/entity/Q37290840

about

Vandetanib in advanced medullary thyroid cancer: review of adverse event management strategies.German Association of Endocrine Surgeons practice guideline for the surgical management of malignant thyroid tumors.Thyroid cancer: SEOM clinical guidelines.Results and summary of voting among the audience during presentation and discussion of Medullary Thyroid Carcinoma clinical guidelines prepared by American Thyroid Association.Clinical comments related to medullary thyroid cancer diagnosis and management.Comprehensive Genomic Profiling of Clinically Advanced Medullary Thyroid Carcinoma.2012 European thyroid association guidelines for metastatic medullary thyroid cancer urge restrained use of novel kinase inhibitors.2012 European thyroid association guidelines for genetic testing and its clinical consequences in medullary thyroid cancer Vandetanib: opening a new treatment practice in advanced medullary thyroid carcinoma.Medullary thyroid cancer diagnosis: an appraisal.Cabozantinib: a review of its use in patients with medullary thyroid cancer.Novel therapies for thyroid cancer.Current Advances in Thyroid Cancer Management. Are We Ready for the Epidemic Rise of Diagnoses?Cabozantinib for the treatment of progressive metastatic medullary thyroid cancer.Consensus on management of advanced medullary thyroid carcinoma on behalf of the Working Group of Thyroid Cancer of the Spanish Society of Endocrinology (SEEN) and the Spanish Task Force Group for Orphan and Infrequent Tumors (GETHI).Surgical management of medullary thyroid carcinoma.Advances in small molecule therapy for treating metastatic thyroid cancer.Postoperative biochemical remission of serum calcitonin is the best predictive factor for recurrence-free survival of medullary thyroid cancer: a large-scale retrospective analysis over 30 years.Results of Surgical Therapy in Patients with Medullary Thyroid Carcinoma.Unusual gastric mucosal infiltration by a medullary thyroid carcinoma: a case report.The management of neuroendocrine tumours: A nutritional viewpoint.Diagnostic utility of PET/CT with 18F-DOPA and 18F-FDG in persistent or recurrent medullary thyroid carcinoma: the importance of calcitonin and carcinoembryonic antigen cutoff.Targeted Therapy for Medullary Thyroid Cancer: A Review.Postoperative Neck Ultrasonography Surveillance After Thyroidectomy in Patients With Medullary Thyroid Carcinoma: A Multicenter Study.SPECT/CT and PET/CT molecular imaging in medullary thyroid carcinoma. Are we running in the right direction?Multimodal imaging with (18)F-FDG-PET/CT and (111)In-Octreotide SPECT in patients with metastatic medullary thyroid carcinoma.Is there a role for fluorine-18 fluorodeoxyglucose positron emission tomography imaging in medullary thyroid cancer?[Medullary thyroid carcinoma].Bone and Calcified Soft Tissue Metastases of Medullary Thyroid Carcinoma Better Characterized on F-Fluoride PET/CT than on Ga-Dotatate PET/CT The 2015 Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma: the “evidence-based” refusal to endorse them by EANM due to the “not evidence-based” marginalization of the role of Nuclear Medicine Navigating Systemic Therapy in Advanced Thyroid Carcinoma: From Standard of Care to Personalized Therapy and Beyond

P2860

Q27692050-464BB319-1448-4365-9BBA-EEA4B0C220AD Q30317867-39F56DAD-393C-4D01-A582-B7D04D28BDEE Q34553635-74DA7862-00C2-4DE9-993A-8FEA28E11F74 Q36690560-DD56E2EC-AC10-4D43-9348-37E7835C3253 Q36690566-B19B74C4-66C3-4F09-A8B7-E19E260C5F17 Q37009001-A1D40223-2068-4C17-A6D6-14943C9BF29A Q37290843-970157D7-8198-4D0B-BB5D-19C9D50E49AC Q37290956-CEAFCA1E-4D36-4186-9BEF-9BDE6E38604D Q38098931-EC2A820E-838B-43D5-8DD5-BB2BE7CB6E41 Q38129820-2B3A345E-C220-4F9E-8C27-6935036A6613 Q38233319-4949D9DC-11D4-40EF-9134-1DB0258CF33F Q38260495-9B507090-09BB-44DE-A427-53ED29440854 Q38614394-93D50C96-99E1-48FB-9990-D61A773FAB1F Q38625034-5B150208-998C-41E7-A189-ADE7BF745E83 Q38674597-614305D3-699C-41DD-9430-B30F5F3C7E1C Q38837195-ACD6798C-2301-435F-954A-FF56B4C3B9BA Q39364787-2EE11E2A-2AC3-498F-B7E9-B94337BC9E20 Q40736049-E71768C1-AB4B-403E-A371-B2FF820CC0D5 Q41731182-EA65104C-9AEA-44C2-AB00-364873EE3003 Q42400842-4A42A583-A615-4FA8-9802-C092143194E1 Q47819836-D9D2E463-7464-446F-955B-A2123FE0DE8A Q48227522-03AAF998-ABB1-4E04-89C6-37375F73498D Q49328959-1FC1DC9C-D5B5-44EB-B397-4528E7F4D163 Q52620581-558ADA40-78E0-42BF-8A26-4A2158E6A846 Q52939430-008E5A5B-78AF-4DB4-B8BD-8B5373D74356 Q52985771-653F0E8F-5CFD-430B-AE81-3D81CB94AC9C Q53151966-7EF549D7-EA7D-4C13-99C0-2D1EC973F3F8 Q53362290-4201166B-2077-4231-8FA4-BB3CF7D7CDE0 Q56524986-3A8C1529-6BB4-4F71-9E82-4FED4860A1C9 Q58005184-0F50641C-EC9F-4444-911A-C8550C1D1CD1 Q58784257-11D68FB6-3159-4498-B731-F3A9120E3280

P2860

2012 European thyroid association guidelines for metastatic medullary thyroid cancer.

http://www.wikidata.org/entity/Q37290840

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 28 March 2012

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

2012 European thyroid association guidelines for metastatic medullary thyroid cancer.

@en

2012 European thyroid association guidelines for metastatic medullary thyroid cancer.

@nl

type

label

2012 European thyroid association guidelines for metastatic medullary thyroid cancer.

@en

2012 European thyroid association guidelines for metastatic medullary thyroid cancer.

@nl

prefLabel

2012 European thyroid association guidelines for metastatic medullary thyroid cancer.

@en

2012 European thyroid association guidelines for metastatic medullary thyroid cancer.

@nl

P1433

Q37290840-8BDAE04E-45AF-4256-86F8-13DE94743191

P1476

Q37290840-855DA4C4-5A78-4080-A1FC-F05C05D34532

P2093

Q37290840-0787DC2A-9176-4EA1-99CE-C77878B2B7CC

Q37290840-23FA26FA-CFD2-47CD-850F-ABB892DFFED1

Q37290840-3937BFC2-4E82-469C-B40F-2F27F13AD252

Q37290840-66CBF361-FAB6-4A76-8FA6-24EF75DFE745

Q37290840-84DED767-2812-4C15-A97F-8B97C49AF5AF

Q37290840-B57569B8-A0AD-4794-A416-76426A23121E

P2860

Q37290840-036574A2-CBC2-42AD-A771-80C0DF900F2C

Q37290840-1058A9B9-79D5-41C7-826F-70BC6DF3EEF1

Q37290840-1C4DAA15-08A2-4941-9F30-DDA751C9AE57

Q37290840-1FC6C540-26DB-438D-B6B6-72FC554913B4

Q37290840-20DCF191-D52D-4D9E-B0C1-7DDDAE5838B4

Q37290840-241CA787-B5CB-4309-B7F1-356035054C60

Q37290840-257EF05D-9196-4BF4-8788-6A1DB9ACDA1A

Q37290840-2F88F0DC-0D48-445E-A656-FF9FAAE7A1A0

Q37290840-346DDE5E-82F3-469A-9DAF-D15FEA217E9E

Q37290840-3A319CB8-A6C2-4B2F-A7B5-BBC8D995C573

P304

Q37290840-E08C639C-27DF-4236-B84A-20764079BB77

P31

Q37290840-18070443-AA38-4801-BDB7-A1A3B399FE20

P356

Q37290840-20C3811A-194A-40D3-AE69-2E226BB0D428

P433

Q37290840-B831B942-AA19-410A-AC2A-954A18CA1FDB

P478

Q37290840-49323EBB-A0C8-4946-9832-22DCA37E505F

P50

Q37290840-19105CAA-8B95-4EAF-B0FF-9E99C968A0A5

P577

Q37290840-D2D7FB50-70F0-48B8-8528-6F3159C4980F

P5875

Q37290840-C5CADE70-DF8E-47A8-8CA3-7CE002367B0C

P698

Q37290840-2154FE37-A66D-4101-8A3F-E2664225A61E

P932

Q37290840-3A59ACC8-E47D-461F-B226-6BD78A58F7E3

P356

P1433

European thyroid journal : official journal of the European Thyroid Association

P1476

2012 European thyroid association guidelines for metastatic medullary thyroid cancer.

@en

P2093

European Thyroid Association Task Force

http://www.w3.org/2001/XMLSchema#string

F Pacini

http://www.w3.org/2001/XMLSchema#string

H Dralle

http://www.w3.org/2001/XMLSchema#string

J W A Smit

http://www.w3.org/2001/XMLSchema#string

L Bastholt

http://www.w3.org/2001/XMLSchema#string

M Schlumberger

http://www.w3.org/2001/XMLSchema#string

P2860

Systems for grading the quality of evidence and the strength of recommendations I: critical appraisal of existing approaches The GRADE Working Group

Phase II clinical trial of sorafenib in metastatic medullary thyroid cancer

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

Airway stenting for the treatment of laryngotracheal stenosis secondary to thyroid cancer

Pamidronate improves the quality of life and induces clinical remission of bone metastases in patients with thyroid cancer

Long-term course of patients with persistent hypercalcitoninemia after apparent curative primary surgery for medullary thyroid carcinoma.

Chemotherapy with dacarbazine and 5-fluorouracil in advanced medullary thyroid cancer.

Vandetanib for the treatment of patients with locally advanced or metastatic hereditary medullary thyroid cancer.

Overview of chronic diarrhea caused by functional neuroendocrine neoplasms.

P304

5-14

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1159/000336977

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

1

http://www.w3.org/2001/XMLSchema#string

P50

Barbara Jarząb

P577

2012-03-28T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

261999629

http://www.w3.org/2001/XMLSchema#string

P698

24782992

http://www.w3.org/2001/XMLSchema#string

P932

3821456

http://www.w3.org/2001/XMLSchema#string